Global Markets for Allergy Diagnostics and Treatments
Global allergy diagnostic and treatment market is projected to increase to nearly $35.3 billion by 2015 from $31.5 billion in 2014. This market is expected to reach $46.8 billion by 2020, corresponding to a compound annual growth rate (CAGR) of 5.8% during 2015 to 2020 period.
- An overview of the global markets for allergy diagnostics and treatments.
- Analyses of global market trends, with data from 2014, estimates for 2015, and projections of CAGRs through 2020.
- Segmentation of the market into diagnostics, prescription treatments, and over-the-counter (OTC) treatments.
- Information on different types of allergic reactions, including anaphylactoid reactions, cytotoxic and cytolytic reactions, immune complex reactions, and delayed hypersensitivity reactions.
- Profiles of major players in the allergy diagnostics and treatments industry.
SCOPE OF REPORT
This BCC Research report is designed to provide a comprehensive look at the global allergy diagnostic, immunotherapy, and treatment markets. The geographic areas covered by the report include the Americas region (i.e., Canada, U.S., Mexico, and Central and South America); the EMRA region (i.e., Europe, the Middle East, Russia, and Africa); and the Asian region (i.e., Japan, China, India, Australia, New Zealand, and other Asian Pacific countries).
The report provides a brief explanation of different allergic disorders with global incidence rates; discusses the different types of allergy diagnostic tests and their applicability in diagnosing various allergens; describes classes of allergy treatment products; and provides an overview of the growing immunotherapy market. The report organizes information from diverse sources into a cohesive unit that includes:
- A section on diagnostic products such as skin prick and patch tests, provocation testing, and antibody allergen testing.
- An overview section on allergies and five categories of prescription allergy products including antihistamines and combinations; sympathomimetics, decongestants and combinations; corticosteroids; mast cell stabilizers; and leukotriene receptors.
- Specific chapters that focus on testing and treatment in three distinct geographical areas: Americas, EMRA and Asia.
- A company profiles section that provides background information on companies active in the diagnostic and treatment arenas.
Prescription and over-the-counter (OTC) medications are further broken down into specific types of administration. Each subsegment is covered in depth with regard to oral, spray, topical, and ocular applications; current treatments, market size, and market participants; potential research and development; and forecasted market size and growth.
Peggy S. Lehr is the BCC research analyst of this report. Ms. Lehr holds a Bachelor of Science degree in Journalism from the University of Colorado, Boulder, and a Master of Science degree in Communication from the University of Denver. Ms. Lehr has been involved with the medical/nursing industry for more than 25 years, and she has worked within the publishing industry for both for-profit and not-for-profit organizations. Recent reports for BCC include health care reports on catheters, magnetic resonance imaging, organ transplantation, asthma and chronic obstructive pulmonary disease (COPD), and autoimmune diseases, and her latest report on the global sterilization market.
- The total, current U.S. prescription allergy treatment and management market in 2001 generated revenues of $6.45 billion. In 2006, this market is forecast to reach $9.6 billion, rising at an average annual growth rate (AAGR) of 8.3%.
- The antihistamines and combinations segment reached $2.90 billion in 2001, some 45% of the market. Growing at an AAGR of 6.7%, this segment will reach $4 billion in 2006, but will lose ground to corticosteroids.
- Corticosteroids are expected to rise the fastest, at an AAGR of 11.8% to $3.98 billion in 2006, representing 41.5% of the market at that time.
- The mast cell stabilizers segment will be the second fastest growing and will rise at an AAGR of 8.9% from $340 million in 2001 to $520 million in 2006.
- Sympathomimetics, decongestants and combinations were valued at $930 million in 2001 and will rise at an AAGR of only 3.2% to $1.09 billion in 2006.